- Home
- TSHA vs RCS Comparison
TSHA vs RCS Comparison
Compare TSHA & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- RCS
- Stock Information
- Founded
- TSHA 2019
- RCS 1994
- Country
- TSHA United States
- RCS United States
- Employees
- TSHA N/A
- RCS N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- RCS Investment Managers
- Sector
- TSHA Health Care
- RCS Finance
- Exchange
- TSHA Nasdaq
- RCS Nasdaq
- Market Cap
- TSHA 313.6M
- RCS 292.8M
- IPO Year
- TSHA 2020
- RCS N/A
- Fundamental
- Price
- TSHA $1.53
- RCS $6.55
- Analyst Decision
- TSHA Strong Buy
- RCS
- Analyst Count
- TSHA 8
- RCS 0
- Target Price
- TSHA $6.63
- RCS N/A
- AVG Volume (30 Days)
- TSHA 2.3M
- RCS 141.1K
- Earning Date
- TSHA 11-13-2024
- RCS 01-01-0001
- Dividend Yield
- TSHA N/A
- RCS 10.12%
- EPS Growth
- TSHA N/A
- RCS N/A
- EPS
- TSHA N/A
- RCS N/A
- Revenue
- TSHA $9,915,000.00
- RCS N/A
- Revenue This Year
- TSHA N/A
- RCS N/A
- Revenue Next Year
- TSHA N/A
- RCS N/A
- P/E Ratio
- TSHA N/A
- RCS N/A
- Revenue Growth
- TSHA N/A
- RCS N/A
- 52 Week Low
- TSHA $1.19
- RCS $4.51
- 52 Week High
- TSHA $4.32
- RCS $6.31
- Technical
- Relative Strength Index (RSI)
- TSHA 34.16
- RCS 41.46
- Support Level
- TSHA $1.56
- RCS $6.26
- Resistance Level
- TSHA $1.75
- RCS $6.59
- Average True Range (ATR)
- TSHA 0.16
- RCS 0.30
- MACD
- TSHA -0.02
- RCS -0.01
- Stochastic Oscillator
- TSHA 3.57
- RCS 41.83
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with this objective.